Copanlisib for People with MCL Previously Treated with Ibrutinib 

Ibrutinib has demonstrated remarkable activity and tolerability in mantle cell lymphoma (MCL). Unfortunately, 30-40% of people with MCL do not respond to ibrutinib, and eventually everybody that does respond will relapse. There is an increasing unmet need for well tolerated treatments with the potential to work after ibrutinib has stopped working. This clinical trial is for men and women with MCL who previously received ibrutinib.